The Medicare GLP-1 Bridge Enrollment Walkthrough: Screens, Forms, and Timelines

What the Bridge Program Is (and What It Isn't)

The Medicare GLP-1 Bridge program launched July 1, 2026, creating the first-ever Medicare pathway for covering obesity medications. Before this, Medicare Part D plans were prohibited by law from covering drugs prescribed solely for weight loss.

The Bridge is a temporary CMS program that operates outside the standard Part D benefit structure. It provides eligible beneficiaries access to specific GLP-1 medications at a $50 monthly copay for each 30-day supply. The program was initially set to end December 31, 2026, but CMS extended it through December 31, 2027, after the BALANCE Model (the planned permanent program) was delayed indefinitely.

What the Bridge covers: Wegovy (injectable and tablet), Zepbound (KwikPen only — not single-dose vials or pens), and Foundayo. What it does not cover: compounded GLP-1 medications, Ozempic (unless prescribed for diabetes), or Mounjaro (unless prescribed for diabetes).

Eligibility Requirements

• You must be actively enrolled in a Medicare Part D plan (standalone PDP or Medicare Advantage with prescription drug coverage - MAPD)
• BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity
• You must NOT already qualify for GLP-1 coverage through Part D for another indication (diabetes, cardiovascular disease, sleep apnea)
• Your prescriber must certify that you're using the GLP-1 as part of a lifestyle program focused on diet and exercise
• Prior authorization from CMS is required — your prescriber submits this

The Enrollment Process: Step by Step

Unlike other Medicare programs, the Bridge doesn't require a separate enrollment. Here's how it works in practice:

Step 1: Visit your prescriber. Schedule an appointment with your primary care physician, endocrinologist, or a telehealth provider who accepts Medicare. Discuss whether GLP-1 treatment is clinically appropriate for you.

Step 2: Prescriber writes the prescription. If you qualify, your prescriber writes a prescription for one of the covered medications (Wegovy, Zepbound KwikPen, or Foundayo) and sends it to your pharmacy.

Step 3: Prior authorization. Your prescriber submits a prior authorization to CMS certifying your eligibility and confirming that the medication is being used alongside a lifestyle modification program. Your pharmacy may request your Medicare Number or the last four digits of your SSN to process the claim.

Step 4: Fill at the pharmacy. Once the prior authorization is approved, you fill the prescription at your pharmacy. You'll pay the $50 copay for each 30-day supply (after meeting your Part D deductible for the year, if you haven't already).

Step 5: Ongoing refills. Refills follow the same process. Your prescriber may need to submit periodic documentation confirming continued medical necessity and participation in a lifestyle program.

Common Questions About the Bridge

Can my telehealth prescriber submit the Bridge PA? Yes, as long as the telehealth provider is enrolled in Medicare and licensed to prescribe in your state. However, the Bridge requires a prescriber certification about lifestyle program participation — telehealth providers should have a mechanism for this.

Does the $50 copay count toward my Part D out-of-pocket costs? CMS has indicated that Bridge program costs operate outside the Part D benefit structure. Check with your Part D plan for specifics on how Bridge costs interact with your deductible and annual out-of-pocket maximum.

What happens when the Bridge ends? The Bridge is currently scheduled to run through December 31, 2027. After that, the BALANCE Model was supposed to launch — but it's been delayed indefinitely. If the Bridge expires without a replacement, Medicare beneficiaries would return to the pre-Bridge status quo: no Part D coverage for GLP-1s prescribed solely for weight loss.

Can I use the Bridge if I was already paying cash for a GLP-1? Yes. If you were self-paying for a brand-name GLP-1 and you meet Bridge eligibility criteria, you can transition to the Bridge program by having your prescriber submit the PA to CMS.